Skip to main content
Retour
JAZZ logo

Jazz Pharmaceuticals plc

Qualité des données : 100%
JAZZ
NASDAQ Healthcare Biotechnology
182,32 €
▲ 1,70 € (0,94%)
Cap. Boursière : 11,22B
Fourchette du Jour
181,00 € 184,48 €
Fourchette 52 Semaines
95,49 € 198,00 €
Volume
666 221
Moyenne 50J / 200J
173,53 € / 144,04 €
Clôture Précédente
180,62 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -31,5 0,4
P/B 2,6 2,9
ROE % -8,5 3,8
Net Margin % -8,4 3,9
Rev Growth 5Y % 8,4 10,0
D/E 1,3 0,2

Objectif de Cours des Analystes

Hold
207,86 € +14.0%
Low: 170,00 € High: 235,00 €
P/E Prévisionnel
7,6
BPA Prévisionnel
23,93 €
Croissance BPA (est.)
+0,0%
CA Est.
4,4 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 31,98 €
30,75 € – 33,42 €
6 B 2
FY2029 30,88 €
29,69 € – 32,27 €
5,8 B 2
FY2028 26,64 €
19,61 € – 32,84 €
5,2 B 4

Points Clés

Revenue grew 8,37% annually over 5 years — modest growth
Earnings declined -163,58% over the past year
Generating 1,30B in free cash flow
PEG of 0,18 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 3,49%
Capital efficient — spends only 1,38% of revenue on capex

Croissance

Revenue Growth (5Y)
8,37%
Revenue (1Y)4,88%
Earnings (1Y)-163,58%
FCF Growth (3Y)10,20%

Qualité

Return on Equity
-8,47%
ROIC1,73%
Net Margin-8,35%
Op. Margin5,26%

Sécurité

Debt / Equity
1,26
Current Ratio1,86
Interest Coverage1,15

Valorisation

P/E Ratio
-31,51
P/B Ratio2,60
EV/EBITDA67,98
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4,88% Revenue Growth (3Y) 5,50%
Earnings Growth (1Y) -163,58% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8,37% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4,27B Net Income (TTM) -356,15M
ROE -8,47% ROA -3,05%
Gross Margin 88,21% Operating Margin 5,26%
Net Margin -8,35% Free Cash Flow (TTM) 1,30B
ROIC 1,73% FCF Growth (3Y) 10,20%
Safety
Debt / Equity 1,26 Current Ratio 1,86
Interest Coverage 1,15 Dividend Yield 0,00%
Valuation
P/E Ratio -31,51 P/B Ratio 2,60
P/S Ratio 2,63 PEG Ratio 0,18
EV/EBITDA 67,98 Dividend Yield 0,00%
Market Cap 11,22B Enterprise Value 15,26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,27B 4,07B 3,83B 3,66B 3,09B
Net Income -356,15M 560,12M 414,83M -224,06M -328,95M
EPS (Diluted) -5,84 8,65 6,10 -3,58 -5,51
Gross Profit 3,76B 3,62B 3,40B 3,12B 2,65B
Operating Income 224,42M 716,63M 578,58M -65,53M 170,28M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 11,66B 12,01B 11,39B 10,84B 12,30B
Total Liabilities 7,34B 7,92B 7,66B 7,75B 8,33B
Shareholders' Equity 4,32B 4,09B 3,74B 3,09B 3,97B
Total Debt 5,42B 6,16B 5,79B 5,81B 6,15B
Cash & Equivalents 1,39B 2,41B 1,51B 881,48M 591,45M
Current Assets 4,17B 4,63B 3,44B 2,61B 2,61B
Current Liabilities 2,24B 1,04B 1,54B 933,19M 809,30M